149 related articles for article (PubMed ID: 7903868)
1. Neuroleptic effects on serine and glycine metabolism.
Baruah S; Waziri R; Sherman A
Biol Psychiatry; 1993 Oct; 34(8):544-50. PubMed ID: 7903868
[TBL] [Abstract][Full Text] [Related]
2. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
Chouinard G; Annable L; Campbell W
J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
[TBL] [Abstract][Full Text] [Related]
3. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
[TBL] [Abstract][Full Text] [Related]
4. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
[TBL] [Abstract][Full Text] [Related]
5. Abnormal serine-glycine metabolism in the brains of schizophrenics.
Waziri R; Baruah S; Sherman AD
Schizophr Res; 1993 Jan; 8(3):233-43. PubMed ID: 8435385
[TBL] [Abstract][Full Text] [Related]
6. Serine metabolism and psychosis.
Waziri R; Wilcox J; Sherman AD; Mott J
Psychiatry Res; 1984 Jun; 12(2):121-36. PubMed ID: 6147868
[TBL] [Abstract][Full Text] [Related]
7. Abnormal serine hydroxymethyl transferase activity in the temporal lobes of schizophrenics.
Waziri R; Baruah S; Hegwood TS; Sherman AD
Neurosci Lett; 1990 Dec; 120(2):237-40. PubMed ID: 2127307
[TBL] [Abstract][Full Text] [Related]
8. Activities of hepatic cytosolic and mitochondrial forms of serine hydroxymethyltransferase and hepatic glycine concentration are affected by vitamin B-6 intake in rats.
Scheer JB; Mackey AD; Gregory JF
J Nutr; 2005 Feb; 135(2):233-8. PubMed ID: 15671219
[TBL] [Abstract][Full Text] [Related]
9. Plasma serine in schizophrenics and controls measured by gas chromatography-mass spectrometry.
Baruah S; Waziri R; Hegwood TS; Mallis LM
Psychiatry Res; 1991 Jun; 37(3):261-70. PubMed ID: 1679949
[TBL] [Abstract][Full Text] [Related]
10. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance.
Altamura AC
Schizophr Res; 1993 Jan; 8(3):187-98. PubMed ID: 8094628
[TBL] [Abstract][Full Text] [Related]
11. Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia.
Sumiyoshi T; Jin D; Jayathilake K; Lee M; Meltzer HY
Int J Neuropsychopharmacol; 2005 Sep; 8(3):451-5. PubMed ID: 15817136
[TBL] [Abstract][Full Text] [Related]
12. Drug effects on serine metabolism in psychiatric patients.
Waziri R; Mott J
Psychiatry Res; 1986 Jun; 18(2):119-26. PubMed ID: 2873604
[TBL] [Abstract][Full Text] [Related]
13. Haloperidol does not affect the level of serum-soluble interleukin-2 receptor in drug-free male schizophrenics.
Kim CE; Kang DY; Ha KS; Jeong SH; Kim YS
Biol Psychiatry; 1995 Dec; 38(12):843-5. PubMed ID: 8750045
[No Abstract] [Full Text] [Related]
14. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
Roose K
Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
[TBL] [Abstract][Full Text] [Related]
15. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
16. RBC and plasma choline in neuroleptic-treated schizophrenic patients.
Lawson WB; Jeste DV; Hanin I; Kopp U; Wyatt RJ
Psychiatry Res; 1989 Jul; 29(1):45-53. PubMed ID: 2570429
[TBL] [Abstract][Full Text] [Related]
17. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
18. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
[TBL] [Abstract][Full Text] [Related]
19. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
Citrome L; Jaffe A; Levine J
Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
[TBL] [Abstract][Full Text] [Related]
20. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
Youssef HA
Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
